Akebia Therapeutics, Inc. (AKBA)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $0.40
- As of
Kresmion compiles this page from AKBA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Akebia Therapeutics, Inc. (AKBA): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-16.
See the full AKBA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AKBA on one page. Preview it with sample data, then open it live with a free account.
Preview the AKBA dossierActive events for AKBA
- high13F: funds added
3 tracked funds increased AKBA this 2026Q3, institutional consensus
- medium13F: new position
Point72 Asset Management, L.P. new position in AKBA
- high13F: large reduction
D. E. Shaw & Co., Inc. cut 75% of AKBA (2026Q3)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +149% to AKBA (2026Q3)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +54% to AKBA (2026Q3)
FREE, NO ACCOUNT
Every event on AKBA, as it fires
You are seeing 5 of 13 events recorded on AKBA since 2026-06-16.
The five above landed across 2 days. The other 8 were recorded on 3 other days. 9 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
AKBA positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| TWO SIGMA INVESTMENTS, LP FundCUSIP 00972D105 · 2026Q3 | $5.6M | n/a |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 00972D105 · 2026Q3 | $1.7M | 0.00% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 00972D105 · 2026Q3 | $1.6M | n/a |
| Point72 Asset Management, L.P. FundCUSIP 00972D105 · 2026Q3 | $1.2M | n/a |
| CITADEL ADVISORS LLC FundCUSIP 00972D105 · 2026Q3 | $958K | n/a |
| D. E. Shaw & Co., Inc. FundCUSIP 00972D105 · 2026Q3 | $20K | n/a |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AKBA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on AKBA
AKBA against its peers
AKBA's operating margin of 9.9% ranks in the 86th percentile of 17 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | AKBA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 236M USD | 81.4M USD | 66 | 15 |
| Gross margin | 83.3% | 43.6% | 84 | 15 |
| Operating margin | 9.9% | -9.1% | 86 | 17 |
| Net margin | -2.3% | -26.1% | 86 | 17 |
| Return on equity | -16.4% | -35.9% | 68 | 13 |
| 1 year | -71.8% | -31.7% | 14 | 17 |
Peers (18): CRDL, DERM, GLAS, TSNDF, BGM, ADCT, CRLBF, GRUSF, CPIX, JUSH, AAWH, ZYBT, CGC, TLPH, LEEEF, ELTP, VREOF, CWBHF. Left out: PHBI (period gap), OGI (period gap), ASRT.D (no annual filing), LFCR (no annual filing), CTOR (no annual filing), BORAY (no annual filing), INCR (period gap). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (AKBA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in AKBA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on AKBA in the last 180 days.
Upstream: SEC EDGAR filings for AKBA
Kresmion, "Akebia Therapeutics, Inc. (AKBA) institutional holdings and SEC filings", data as of 2026-11-18, https://kresmion.com/research/AKBA. Upstream data: SEC EDGAR filings for AKBA.
Link to this data (HTML):
<a href="https://kresmion.com/research/AKBA">Akebia Therapeutics, Inc. (AKBA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow AKBA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to AKBA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.